newsfilter
← Latest News
ACCESS Newswire·

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Folate receptor alpha targeting drug conjugate & hexa silanol exatecan payloads tested in animal models of ovarian cancerStrong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancerStrong safety